HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence.

Abstract
There are theoretical limits to the efficacy of intravesical chemotherapy for prevention of tumor recurrence after transurethral resection of a superficial bladder cancer. Our multi-institutional studies revealed that the direct efficacy of BCG, intravesical instillation for treatment of an existing tumor is very promising. This efficacy persisted over a long period of time, and the subsequent recurrence rate was markedly reduced. Bladder cancer, sometimes earlier known as an occupational disease, might be related to unknown chemical carcinogens. Since enterobacterias are thought to produce carcinogens and mutagens, including nitroso-compounds in the intestinal tract, BLP (lactobacillus casei preparation), treatment may suppress the production of such compounds by altering the intestinal flora. Preclinical studies have demonstrated that BLP suppresses the development of bladder cancer induced by N-butyl-N-(4-hydroxy-butly)-nitrosamine in mice and rats. A double-blind clinical trial recently revealed that BLP was effective for preventing the recurrence of superficial bladder cancer. Bropirimine, a interferon inducer, is now an internationally developing agent for superficial bladder cancer, which is discussed on the basis of Japanese phase II trial data.
AuthorsH Akaza
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 24 Suppl 1 Pg. 253-6 (May 1997) ISSN: 0385-0684 [Print] Japan
PMID9210905 (Publication Type: Journal Article, Review)
Chemical References
  • BCG Vaccine
  • Interferon Inducers
  • Butylhydroxybutylnitrosamine
  • Cytosine
  • bropirimine
Topics
  • Administration, Intravesical
  • Animals
  • BCG Vaccine (therapeutic use)
  • Butylhydroxybutylnitrosamine
  • Carcinoma, Transitional Cell (prevention & control)
  • Clinical Trials as Topic
  • Clinical Trials, Phase II as Topic
  • Cytosine (administration & dosage, analogs & derivatives)
  • Humans
  • Interferon Inducers (administration & dosage)
  • Mice
  • Multicenter Studies as Topic
  • Neoplasm Recurrence, Local (prevention & control)
  • Rats
  • Urinary Bladder Neoplasms (chemically induced, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: